Skip Navigation LinksHome > April 2012 - Volume 18 - Issue 2, Neuro-oncology > Helping Patients Make the Best Decision Regarding Duration o...
CONTINUUM: Lifelong Learning in Neurology:
doi: 10.1212/01.CON.0000413668.65668.4a
Practice Issues

Helping Patients Make the Best Decision Regarding Duration of Temozolomide Chemotherapy Treatment

Groves, Morris D. Jr MD, JD; Plummer, Ava B. MPH, JD

Collapse Box

Abstract

Outcomes for patients with glioblastoma have improved with the addition of temozolomide (TMZ) chemotherapy to radiation therapy followed by adjuvant TMZ for up to 1 year. Patients often wish to continue chemotherapy after the standard 1-year course. Whether to continue or to stop TMZ is a complex and stressful decision for the patient and family, and the decision should be based on a discussion of the known risks and benefits of each choice.

© 2012 American Academy of Neurology

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login